BMY
Income statement / Annual
Last year (2025), Bristol-Myers Squibb Co.'s total revenue was $48.20 B,
a decrease of 0.22% from the previous year.
In 2025, Bristol-Myers Squibb Co.'s net income was $7.05 B.
See Bristol-Myers Squibb Co.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$48.20 B |
$48.30 B |
$45.01 B |
$46.16 B |
$46.39 B |
$42.52 B |
$26.15 B |
$22.56 B |
$20.78 B |
$19.43 B |
| Cost of Revenue |
$13.94 B
|
$13.97 B
|
$10.69 B
|
$10.14 B
|
$9.94 B
|
$11.77 B
|
$8.08 B
|
$6.47 B
|
$6.01 B
|
$4.97 B
|
| Gross Profit |
$34.26 B
|
$34.33 B
|
$34.31 B
|
$36.02 B
|
$36.45 B
|
$30.75 B
|
$18.07 B
|
$16.09 B
|
$14.76 B
|
$14.46 B
|
| Gross Profit Ratio |
0.71
|
0.71
|
0.76
|
0.78
|
0.79
|
0.72
|
0.69
|
0.71
|
0.71
|
0.74
|
| Research and Development Expenses |
$9.95 B
|
$11.16 B
|
$9.30 B
|
$9.51 B
|
$10.20 B
|
$11.14 B
|
$6.15 B
|
$6.33 B
|
$6.47 B
|
$5.01 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$162.00 M
|
$91.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$7.81 B
|
$7.69 B
|
$7.66 B
|
$4.87 B
|
$4.55 B
|
$4.75 B
|
$4.98 B
|
| Selling, General & Administrative Expenses |
$7.27 B
|
$8.41 B
|
$7.77 B
|
$7.81 B
|
$7.69 B
|
$7.66 B
|
$4.87 B
|
$4.55 B
|
$4.75 B
|
$4.98 B
|
| Other Expenses |
$3.32 B
|
$8.87 B
|
$9.05 B
|
$9.60 B
|
$10.02 B
|
$9.76 B
|
$1.14 B
|
$97.00 M
|
$97.00 M
|
$0.00
|
| Operating Expenses |
$20.54 B
|
$28.45 B
|
$26.12 B
|
$26.92 B
|
$27.91 B
|
$28.57 B
|
$12.15 B
|
$10.98 B
|
$11.32 B
|
$9.99 B
|
| Cost And Expenses |
$34.47 B
|
$42.41 B
|
$36.81 B
|
$37.06 B
|
$37.85 B
|
$40.34 B
|
$20.23 B
|
$17.45 B
|
$17.33 B
|
$14.96 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.89 B
|
$1.95 B
|
$1.17 B
|
$1.23 B
|
$1.33 B
|
$1.42 B
|
$656.00 M
|
$183.00 M
|
$196.00 M
|
$167.00 M
|
| Depreciation & Amortization |
$4.01 B
|
$9.60 B
|
$9.76 B
|
$10.28 B
|
$10.69 B
|
$10.38 B
|
$1.75 B
|
$637.00 M
|
$789.00 M
|
$382.00 M
|
| EBITDA |
$15.23 B |
$3.17 B |
$19.37 B |
$19.22 B |
$20.12 B |
$4.93 B |
$7.38 B |
$6.79 B |
$6.12 B |
$6.46 B |
| EBITDA Ratio |
0.32
|
0.07
|
0.43
|
0.42
|
0.43
|
0.12
|
0.28
|
0.3
|
0.29
|
0.33
|
| Operating Income Ratio |
0.28
|
0.12
|
0.18
|
0.2
|
0.18
|
0.05
|
0.23
|
0.23
|
0.17
|
0.23
|
| Total Other Income/Expenses Net |
-$4.40 B
|
-$14.27 B
|
$245.00 M
|
-$1.39 B
|
-$439.00 M
|
-$9.05 B
|
-$938.00 M
|
$854.00 M
|
$1.69 B
|
$1.45 B
|
| Income Before Tax |
$9.33 B
|
-$8.38 B
|
$8.44 B
|
$7.71 B
|
$8.10 B
|
-$6.87 B
|
$4.98 B
|
$5.97 B
|
$5.13 B
|
$5.92 B
|
| Income Before Tax Ratio |
0.19
|
-0.17
|
0.19
|
0.17
|
0.17
|
-0.16
|
0.19
|
0.26
|
0.25
|
0.3
|
| Income Tax Expense |
$2.27 B
|
$554.00 M
|
$400.00 M
|
$1.37 B
|
$1.08 B
|
$2.12 B
|
$1.52 B
|
$1.02 B
|
$4.16 B
|
$1.41 B
|
| Net Income |
$7.05 B
|
-$8.95 B
|
$8.03 B
|
$6.33 B
|
$6.99 B
|
-$9.02 B
|
$3.44 B
|
$4.92 B
|
$1.01 B
|
$4.46 B
|
| Net Income Ratio |
0.15
|
-0.19
|
0.18
|
0.14
|
0.15
|
-0.21
|
0.13
|
0.22
|
0.05
|
0.23
|
| EPS |
3.46 |
-4.41 |
3.88 |
2.97 |
3.15 |
-3.98 |
2.02 |
3.03 |
0.61 |
2.67 |
| EPS Diluted |
3.45 |
-4.41 |
3.86 |
2.95 |
3.12 |
-3.98 |
2.01 |
3.03 |
0.61 |
2.65 |
| Weighted Average Shares Out |
$2.04 B
|
$2.03 B
|
$2.07 B
|
$2.13 B
|
$2.22 B
|
$2.26 B
|
$1.71 B
|
$1.63 B
|
$1.65 B
|
$1.67 B
|
| Weighted Average Shares Out Diluted |
$2.04 B
|
$2.03 B
|
$2.08 B
|
$2.15 B
|
$2.25 B
|
$2.26 B
|
$1.71 B
|
$1.64 B
|
$1.65 B
|
$1.68 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
